Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2016, Article ID 2872371, 7 pages
http://dx.doi.org/10.1155/2016/2872371
Clinical Study

Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients

1Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, MBC-11, P.O. Box 3354, Riyadh 11211, Saudi Arabia
2Alfaisal University, College of Medicine, Riyadh, Saudi Arabia
3Liver & Small Bowel Transplant and Hepatobiliary and Pancreatic Surgery-Organ Transplant Center, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
4King Saud University, College of Medicine, Riyadh, Saudi Arabia

Received 3 November 2015; Accepted 10 November 2015

Copyright © 2016 A. Ajlan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization Hepatitis C Fact sheet no.164, March 2014, http://www.who.int/mediacentre/factsheets/fs164/en/.
  2. W. R. Kim, “The burden of hepatitis C in the United States,” Hepatology, vol. 36, no. 5, supplement 1, pp. S30–S34, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Prieto, M. Berenguer, J. M. Rayón et al., “High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes,” Hepatology, vol. 29, no. 1, pp. 250–256, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Berenguer, “Natural history of recurrent hepatitis C,” Liver Transplantation, vol. 8, no. 10, supplement 1, pp. S14–S18, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Malkan, A. Humar, L. Lilly et al., “Natural history of recurrent hepatitis C after liver transplantation,” Transplantation Proceedings, vol. 33, no. 1-2, p. 1468, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. E. J. Gane, “The natural history of recurrent hepatitis C and what influences this,” Liver Transplantation, vol. 14, no. 2, pp. S36–S44, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Berenguer, “What determines the natural history of recurrent hepatitis C after liver transplantation?” Journal of Hepatology, vol. 42, no. 4, pp. 448–456, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. F. P. Picciotto, G. Tritto, A. G. Lanza et al., “Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation,” Journal of Hepatology, vol. 46, no. 3, pp. 459–465, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. M. El-Hazmi, “Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the Central region of Saudi Arabia,” Saudi Medical Journal, vol. 25, no. 1, pp. 26–33, 2004. View at Google Scholar · View at Scopus
  10. S. R. Mehdi, A. Pophali, and K. A. Al-Abdul Rahim, “Prevalence of hepatitis B and C among blood donors,” Saudi Medical Journal, vol. 21, no. 10, pp. 942–944, 2000. View at Google Scholar · View at Scopus
  11. T. A. Madani, “Hepatitis C virus infections reported in Saudi Arabia over 11 years of surveillance,” Annals of Saudi Medicine, vol. 27, no. 3, pp. 191–194, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. A. A. Abdo, F. M. Sanai, and F. Z. Al-Faleh, “Epidemiology of viral hepatitis in Saudi Arabia: are we off the hook?” Saudi Journal of Gastroenterology, vol. 18, no. 6, pp. 349–357, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. S. Abdel-Moneim, M. S. Bamaga, G. M. G. Shehab, A.-A. S. A. Abu-Elsaad, and F. M. Farahat, “HCV infection among Saudi population: high prevalence of genotype 4 and increased viral clearance rate,” PLoS ONE, vol. 7, no. 1, Article ID e29781, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Berenguer, “Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin,” Journal of Hepatology, vol. 49, no. 2, pp. 274–287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Xirouchakis, C. Triantos, P. Manousou et al., “Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies,” Journal of Viral Hepatitis, vol. 15, no. 10, pp. 699–709, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. C. S. Wang, H. H. Ko, E. M. Yoshida, C. A. Marra, and K. Richardson, “Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis,” American Journal of Transplantation, vol. 6, no. 7, pp. 1586–1599, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. Drugs@FDA: Sofosbuvir, February 2014, http://www.accessdata.fda.gov/Scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
  18. E. J. Gane, C. A. Stedman, R. H. Hyland et al., “Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C,” The New England Journal of Medicine, vol. 368, no. 1, pp. 34–44, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. K. V. Kowdley, E. Lawitz, I. Crespo et al., “Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial,” The Lancet, vol. 381, no. 9883, pp. 2100–2107, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Lawitz, J. P. Lalezari, T. Hassanein et al., “Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial,” The Lancet Infectious Diseases, vol. 13, no. 5, pp. 401–408, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Lalezari, D. Nelson, R. Hyland et al., “845 Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naïve patients with HCV infection: the QUANTUM study,” Journal of Hepatology, vol. 58, supplement 1, p. S346, 2013. View at Publisher · View at Google Scholar
  22. E. Lawitz, A. Mangia, D. Wyles et al., “Sofosbuvir for previously untreated chronic hepatitis C infection,” The New England Journal of Medicine, vol. 368, no. 20, pp. 1878–1887, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. I. M. Jacobson, S. C. Gordon, K. V. Kowdley et al., “Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options,” New England Journal of Medicine, vol. 368, no. 20, pp. 1867–1877, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Osinusi, E. G. Meissner, Y.-J. Lee et al., “Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial,” The Journal of the American Medical Association, vol. 310, no. 8, pp. 804–811, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. J.-M. Pawlotsky, “Treatment of chronic hepatitis C: current and future,” Current Topics in Microbiology and Immunology, vol. 369, pp. 321–342, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. AASLD/IDSA, “Recommendations for Testing, Managing, and Treating Hepatitis C,” http://www.hcvguidelines.org/full-report-view.
  27. M. Berenguer, M. Prieto, J. M. Rayón et al., “Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation,” Hepatology, vol. 32, no. 4 I, pp. 852–858, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Charlton, E. Seaberg, R. Wiesner et al., “Predictors of patient and graft survival following liver transplantation for hepatitis C,” Hepatology, vol. 28, no. 3, pp. 823–830, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. J. R. Williams, “The Declaration of Helsinki and public health,” Bulletin of the World Health Organization, vol. 86, no. 8, pp. 650–652, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Ascha, M. Ascha, N. N. Zein et al., “Treatment of recurrent hepatitis C genotype-4 post-liver transplantation with sofosbuvir plus simeprevir,” International Journal of Organ Transplantation Medicine, vol. 6, no. 2, pp. 86–90, 2015. View at Google Scholar · View at Scopus
  31. M. Charlton, E. Gane, M. P. Manns et al., “Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation,” Gastroenterology, vol. 148, no. 1, pp. 108–117, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. M. R. Charlton, E. J. Gane, M. P. Manns et al., “Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective, multicenter study,” in Program and Abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases, Abstract LB-2, Washington, DC, USA, November 2013.
  33. S. Lens, M. Gambato, M.-C. Londoño, and X. Forns, “Interferon-free regimens in the liver-transplant setting,” Seminars in Liver Disease, vol. 34, no. 1, pp. 58–71, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. X. Forns, M. Prieto, M. Charlton et al., “O62 sofosbuvir compassionate use program for patients with severe recurrent hepatitis c including fibrosing cholestatic hepatitis following liver transplantation,” Journal of Hepatology, vol. 60, no. 1, supplement, p. S26, 2014. View at Publisher · View at Google Scholar
  35. R. Satokar, J. Ahn, H. Te et al., “Sofosbuvir as the backbone of treatment for HCV after liver transplantation: a real-life multicenter experience,” in Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting, pp. 532A–545A, Boston, Mass, USA, October 2014.
  36. K. Deterding, C. Höner zu Siederdissen, K. Port et al., “Delayed early HCV RNA response during IFN-free therapy with sofosbuvir in interferon-ineligible patients with advanced cirrhosis,” in Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting, pp. 659A–709A, Boston, Mass, USA, October 2014.
  37. N. H. Bzowej, S. Joshi, G. Therapondos et al., “Post-transplant treatment of severe recurrent hepatitis C (HCV) with daclatasvir and sofosbuvir plus or minus Ribavirin,” in Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting, Hepatology, pp. 542A–543A, Boston, Mass, USA, October 2014.
  38. R. J. Fontana, E. A. Hughes, M. Bifano et al., “Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C,” American Journal of Transplantation, vol. 13, no. 6, pp. 1601–1605, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. A. M. Pellicelli, M. Montalbano, R. Lionetti et al., “Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late,” Digestive and Liver Disease, vol. 46, no. 10, pp. 923–927, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Chatterjee, P. F. Smith, and A. S. Perelson, “Hepatitis C viral kinetics. the past, present, and future,” Clinics in Liver Disease, vol. 17, no. 1, pp. 13–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Guedj, P. S. Pang, J. Denning et al., “Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938,” Antiviral Therapy, vol. 19, no. 2, pp. 211–220, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. X. Forns, M. García-Retortillo, T. Serrano et al., “Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation,” Journal of Hepatology, vol. 39, no. 3, pp. 389–396, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Gaglio, C. E. Glick, and J. Reinus, “Survey on pre- and post-transplant management of hepatitis C: response from medical directors of US transplant programs,” in Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting, Hepatology, p. 544A, Boston, Mass, USA, October 2014.
  44. M. P. Curry, X. Forns, R. T. Chung et al., “Sofosbuvir and ribavirin prevent recurrence of hcv infection after liver transplantation: an open-label study,” Gastroenterology, vol. 148, no. 1, pp. 100–107.e1, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Tischer and R. J. Fontana, “Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting,” Journal of Hepatology, vol. 60, no. 4, pp. 872–884, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Huard, B. Kim, A. Patel et al., “Early safety and efficacy profiles of renal transplant recipients with chronic hepatitis C treated with sofosbuvir and ribavirin,” in Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting, Hepatology, pp. 532A–545A, Boston, Mass, USA, October 2014.
  47. F. K. A. Gordon, S. Coombs, P. Goucher, E. Aljahdli, and E. Pomfret, “Sofosbuvir + simeprevir is safe in liver transplant recipients,” in Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting, Hepatology, p. 543A, Boston, Mass, USA, October 2014.
  48. I. P. R. Suliman, Y. Kady, C. Hill, T. Couturier, P. Reshamwala, and T. Hassanein, “The combination of simeprevir and sofosbuvir for the treatment of HCV infection in patients post liver transplant with significant fibrosis,” in Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting, Heptaology, p. 545A, Boston, Mass, USA, October 2014.